within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A03B_BelladonnaAndDerivativesPlain.A03BB05_CimetropiumBromide;

model CimetropiumBromide
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.03,
    Cl = 2.777777777777778e-06,
    adminDuration = 600,
    adminMass = 10 / 1000000,
    adminCount = 1,
    Vd = 0.0007,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0005,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>CimetropiumBromide</td></tr><tr><td>ATC code:</td><td>A03BB05</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>10</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.7</td><td>L</td></tr>
    <tr><td>clearance:</td><td>10</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Cimetropium bromide is a quaternary ammonium antimuscarinic agent used as an antispasmodic for the relief of gastrointestinal disorders such as irritable bowel syndrome, peptic ulcer, and abdominal pain. The drug is not widely approved in the United States but has been used in some countries for these indications.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for typical healthy adult after oral administration; no published human PK studies available.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.A.A03BB05 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end CimetropiumBromide;
